Joan-Lluis Vives Corrons

Designation:

Professor

Department:

Hematology

University:

University of Barcelona

Country:

Spain

Email:

jlvives@clinic.cat

Journal Associated: Archives of Hematology Case Reports and Reviews Biography:

Biography: Prof. Joan Lluís Vives Corrons is Professor Emeritus at the University of Barcelona and an honorary researcher at the Josep Carreras Institute for Leukaemia Research (IJC). He has an extensive background in diagnosing rare anemias and studying the molecular bases of red blood cell (RBC) enzymopathies, membranopathies, and hemoglobinopathies.

Over more than 30 years, he served as head of the Haematology Laboratory Department (1976-1997) and head of the Red Blood Cell Pathology Unit (1998-2016). His research has focused on the physiopathology of anemia, particularly the molecular and genetic mechanisms of congenital anemias related to RBCs and erythropoietic defects. He has been the principal investigator (PI) for over 35 research projects, primarily on erythroenzymopathies like glucose-6-phosphate dehydrogenase (G6PD) and pyruvate kinase (PK) deficiencies, hemoglobinopathies such as sickle-cell disease (SCD) and thalassemia, and hereditary hemolytic anemias (HHA) due to RBC membranopathies.

In 2002, Prof. Vives Corrons became the coordinator of the European Network for Rare and Congenital Anaemias (ENERCA), co-financed by the European Commission (EC) under its Public Health System (SANCO-Public Health). ENERCA aimed to establish a pan-European network for the diagnosis, registry, and treatment of rare anemias (RA) in Europe. Currently, he serves as chairman of the Scientific Board of the Rare Anemias International Network (RAIN), supported by the Thalassemia International Federation (TIF).

Research Interest: principal investigator (PI) for over 35 research projects, primarily on erythroenzymopathies like glucose-6-phosphate dehydrogenase (G6PD) and pyruvate kinase (PK) deficiencies,

hemoglobinopathies such as sickle-cell disease (SCD) and thalassemia, and hereditary hemolytic anemias (HHA) due to RBC membranopathies